Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from D. Boral Capital

Key Points

• Coya Therapeutics' stock has been given a "buy" rating by D. Boral Capital, with a target price of $18.00, indicating a potential upside of 217.46% from its previous close.
• The company posted a quarterly loss of ($0.36) EPS, missing analysts' estimates, and reported a revenue of only $0.16 million compared to expectations of $0.78 million.
• Despite mixed ratings from analysts, there is a consensus rating of "Buy" for Coya Therapeutics, with a consensus price target of $16.50 across multiple reports.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating reissued by analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $18.00 price target on the stock. D. Boral Capital's target price would suggest a potential upside of 227.27% from the company's current price.

Other equities research analysts also recently issued research reports about the company. Chardan Capital reissued a "buy" rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Wednesday, August 13th. HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a report on Monday, August 25th. Lake Street Capital started coverage on Coya Therapeutics in a report on Wednesday, July 9th. They issued a "buy" rating and a $16.00 price target for the company. Finally, Wall Street Zen downgraded Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Four research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $16.50.

Coya Therapeutics Stock Performance

COYA stock traded down $0.24 during trading on Wednesday, reaching $5.50. 65,309 shares of the company traded hands, compared to its average volume of 114,848. Coya Therapeutics has a 12 month low of $4.65 and a 12 month high of $10.24. The business has a 50 day simple moving average of $6.19 and a 200 day simple moving average of $6.03. The company has a market capitalization of $91.99 million, a price-to-earnings ratio of -4.44 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.14). The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.78 million. As a group, research analysts forecast that Coya Therapeutics will post -1.15 EPS for the current year.

Hedge Funds Weigh In On Coya Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in COYA. Dauntless Investment Group LLC acquired a new position in Coya Therapeutics during the first quarter worth $1,083,000. CM Management LLC lifted its stake in shares of Coya Therapeutics by 25.0% in the 1st quarter. CM Management LLC now owns 200,000 shares of the company's stock valued at $1,294,000 after purchasing an additional 40,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Coya Therapeutics in the 2nd quarter valued at $119,000. Jane Street Group LLC lifted its stake in shares of Coya Therapeutics by 101.7% in the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock valued at $169,000 after purchasing an additional 13,176 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Coya Therapeutics in the 1st quarter valued at $65,000. Institutional investors and hedge funds own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.